N
CLDX icon

Natixis’s Celldex Therapeutics CLDX Stock Holding History

Natixis’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-232,188
Closed -$4.16M – 1054
2025
Q1 		$4.16M Buy
232,188
+216,388
+1,370% +$4.83M 0.02% 333
2024
Q4 		$399K Buy
+15,800
New +$429K ﹤0.01% 736
2024
Q3 		– Sell
-165,500
Closed -$6.13M – 985
2024
Q2 		$6.13M Sell
165,500
-48,400
-23% -$1.83M 0.04% 274
2024
Q1 		$8.98M Buy
+213,900
New +$8.78M 0.05% 249

Other funds holding CLDX

KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Natixis's CLDX Position: Q2 2025 in Review

Natixis sold out of Celldex Therapeutics (CLDX) in Q2 2025, closing a stake of 232,188 shares — an estimated $4.16M sold.

Natixis first reported a position in CLDX in Q1 2024 and held it in 4 quarters. The position peaked at $8.98M in Q1 2024. 180 funds tracked by Wall St. Rank hold CLDX as of Q2 2025.

  • Natixis reported no remaining Celldex Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Natixis sold 232,188 Celldex Therapeutics shares in Q2 2025, an estimated $4.16M.
  • Natixis first reported a position in Celldex Therapeutics in Q1 2024 and held it in 4 quarters.
  • Natixis's Celldex Therapeutics position peaked at $8.98M in Q1 2024.
  • 180 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2025.

Based on Natixis's 13F filing for Q2 2025, filed 13 Aug 2025.